Please login to the form below

Not currently logged in
Email:
Password:

Marc Becker joins CRISPR Therapeutics

He becomes chief financial officer

CRISPR Therapeutics Marc BeckerCRISPR Therapeutics has appointed Marc Becker as its new chief financial officer with remit to drive development of its gene-editing technology platform.

Becker brings over 20 years of commercial, operational and corporate finance expertise to the role, having held senior positions at BankBoston, Genzyme, KPMG and rEVO Biologics.

He joins the Switzerland-headquartered biopharmaceutical company from rEVO Biologics, where he served as its chief financial officer from 2012 until February this year.

While at rEVO, Becker was responsible for leading the finance department, directing the firm's market strategy and managing its governance.

Rodger Novak, chief executive officer of CRISPR Therapeutics, said: “Marc's extensive network and proven track record to establish internal controls will be vital as we continue to engage in key strategic ventures to support the discovery, development and commercialisation of new breakthrough therapeutics.”

Becker said: “I am excited to join the CRISPR Therapeutics leadership team as the company's growth accelerates with the introduction of strategic partnerships and ventures.

“Our technology is truly revolutionary and I'm delighted to be part of the team that will enable the development of life-changing medicines.”

21st March 2016

From: Sales

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
KVA Digital

KVA is an award winning full-service digital communications & brand experience agency. Our healthcare expertise blends creative ‘outside-the-box’ thinking with...

Latest intelligence

Mistrust in medical research: a patient perspective
The recent development of several COVID-19 vaccines has placed medical research firmly in the spotlight, highlighting public confusion and misinformation about clinical trials. Patient advocate, Trishna Bharadia reveals what the...
Real-world evidence: breaking boundaries in rare disease
Generating data for drug launches is a challenging process. In rare diseases, with small patient populations and high unmet need, evidence generation is even more complex. Consultant Sarah Poole and...
The heavy toll of COVID-19 on cancer patients
We all know that finding and treating cancer early saves lives. During the COVID-19 pandemic, oncology treatments paused while cancer continued to spread. So, what has been the impact of...

Infographics